Skip to content
Open access · CC-BY via OpenAlex

Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease

Fernando González‐Ortiz, Bjørn‐Eivind Kirsebom, José Contador, Jordan E. Tanley, Per Selnes, Berglind Gísladóttir, Lene Pålhaugen, Mathilde Suhr Hemminghyth, Jonas Alexander Jarholm, Ragnhild Eide Skogseth, Geir Bråthen, Gøril Grøndtvedt, Atle Bjørnerud, Sandra R.R. Tecelão, Knut K. Waterloo

Nature Communications · 2024 · ▲ 86 citations

Abstract

Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood, phosphorylated tau (p-tau) associates with Aβ pathophysiology but an AD-type neurodegeneration biomarker has been lacking. In this multicenter study (n = 1076), we show that brain-derived tau (BD-tau) in blood increases according to concomitant Aβ ("A") and neurodegeneration ("N") abnormalities (determined using cerebrospinal fluid biomarkers); We used blood-based A/N biomarkers to profile the participants in this study; individuals with blood-based p-tau+/BD-tau+ profiles had the fastest cognitive decline and atrophy rates, irrespective of the baseline cognitive status. Furthermore, BD-tau showed no or much weaker correlations with age, renal function, other comorbidities/risk factors and self-identified race/ethnicity, compared with other blood biomarkers. Here we show that blood-based BD-tau is a biomarker for identifying Aβ-positive individuals at risk of short-term cognitive decline and atrophy, with implications for clinical trials and implementation of anti-Aβ therapies.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1038/s41467-024-47286-5
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
González‐Ortiz, F., Kirsebom, B., Contador, J., Tanley, J.E., Selnes, P., Gísladóttir, B., Pålhaugen, L., Hemminghyth, M.S., Jarholm, J.A., Skogseth, R.E., Bråthen, G., Grøndtvedt, G., Bjørnerud, A., Tecelão, S.R., Waterloo, K.K., Aarsland, D., Fernández‐Lebrero, A., García‐Escobar, G., Navalpotro‐Gómez, I., &amp; Turton, M. (2024). Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. <em>Nature Communications</em>. https://doi.org/10.1038/s41467-024-47286-5
Vancouver
González‐Ortiz F, Kirsebom B, Contador J, Tanley JE, Selnes P, Gísladóttir B, et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. Nature Communications. 2024. doi:10.1038/s41467-024-47286-5.
BibTeX
@article{fernando2024Plasma, title = {Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease}, author = {Fernando González‐Ortiz and Bjørn‐Eivind Kirsebom and José Contador and Jordan E. Tanley and Per Selnes and Berglind Gísladóttir and Lene Pålhaugen and Mathilde Suhr Hemminghyth and Jonas Alexander Jarholm and Ragnhild Eide Skogseth and Geir Bråthen and Gøril Grøndtvedt and Atle Bjørnerud and Sandra R.R. Tecelão and Knut K. Waterloo and Dag Aarsland and Aida Fernández‐Lebrero and Greta García‐Escobar and Irene Navalpotro‐Gómez and Michael Turton and Agnes Hesthamar and Przemysław Radosław Kac and Johanna Nilsson and Jose Alejandro Luchsinger and Kathleen M. Hayden}, journal = {Nature Communications}, year = {2024}, doi = {10.1038/s41467-024-47286-5}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings